

November 2021



Medicines Formulary Additions

- RED** **Buprenorphine (Buvidal®) injection** added to Formulary for patients already on therapy who require continuation whilst in secondary care. Initiation by addiction services only.
- RED** **Infliximab (Remsima®) pre-filled pen** for subcutaneous injection added as an option for patients stabilised on intravenous therapy in line with NICE and local guidance
- SCG** **Exenatide (Bydureon BCize®) pen** replaces Bydureon MR 2mg pen (discontinued product) - Beds/Luton Formulary only
- GREEN** **Sodium hyaluronate eye drops (Eyeaze®)** added for the treatment of severe dry eye.
- GREEN** **Carbomer 0.2% preservative free eye drops (Evolve)** added as a cost-effective option for dry eye where patients cannot tolerate preservatives.
- GREEN** **SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin)** are now green status with additional advice:
 - Refer patients already on insulin to a specialist diabetes teams for initiation of an SGLT2 inhibitor.
 - Seek advice and guidance from specialist teams if unsure of how to initiate SGLT2 inhibitors for patients already on sulphonylurea/or those predisposed to hypoglycaemic events.
 - Counsel all patients starting SGLT2 about the risk of DKA. DKA Patient Leaflet can be accessed via [this link](#)
- AMBER** **AMB 3** **Testosterone gels** For low sexual desire in post-menopausal women. A [fact sheet](#) is available to assist prescribing.

NICE Technology Appraisals where new entries added to the Formulary

- [TA729 Sapropterin](#) for treating hyperphenylalaninaemia in phenylketonuria (NHSE commissioned)
- [TA738 Berotralstat](#) for preventing recurrent attacks of hereditary angioedema (NHSE commissioned)
- [TA740 Apalutamide](#) with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (NHSE commissioned)
- [TA733 Inclisiran](#) for treating primary hypercholesterolaemia or mixed dyslipidaemia (CCG commissioned)
- [TA744 Upadacitinib](#) for treating moderate rheumatoid arthritis (CCG commissioned)

Medicines Formulary Deletions

- Dapagliflozin is no longer licensed for treatment of Type 1 diabetes. See [link](#) for more information & Formulary entries
- Simple eye ointment removed from MK formulary (alignment with Bedford/Luton)
- Removal of Konakion® brand (discontinued)—now prescribed as generic phytomenadione injection

Wound Care Formulary additions

- **Urgoclean & Urgostart Plus** added for the management of diabetic foot ulcers and venous leg ulcers.

Tocilizumab: [Supply disruption alert](#)

Supplies of tocilizumab are limited—see link above for further information on management.

Melatonin liquid 1mg/1ml— Kidmel® unlicensed special should be prescribed for patients under 5 due to safer excipient profile. Colonis brand can be used for patients age 5 and above. See Formulary for further information.

SCG Beds/Luton **AMB 1** Milton Keynes

Bedford & Luton:

RED	Hospital only prescribing
AMBER	Suitable for GP prescribing following specialist initiation
GREEN	Initiation in primary or secondary care within licensed/local recommendation
SCG	Specialist initiation & stabilisation followed by GP continuation in line with shared care guideline
BLACK	Product rejected locally or nationally. Do not prescribe.

Milton Keynes:

RR	Assessed and NOT approved for use by MKPAG. Do not prescribe.
RED	Hospital only prescribing
AMB 1	Specialist recommendation followed by GP initiation and continuation
AMB 2	Specialist or GP initiation in line with local guidance after 1st line failure, followed by GP continuation
AMB 3	Specialist initiation & stabilisation followed by GP continuation
GREEN	Routine prescribing within licensed indication
SCG	Specialist initiation & stabilisation followed by GP continuation in line with shared care guideline